---

Highlights for March 2018

1. Zydus Cadila partners with Medicure to commercialize its 505(b)(2) New Drug Application product, pitavastatin magnesium (ZYPITAMAGTM) in USA
2. Sahajanand Medical Technologies, the leading manufacturer of cardiac stents in India, announces a strategic partnership with Cordis, Cardinal Health’s interventional vascular business
3. ChrysCap to invest $20M in Chennai-based skin care products firm Curatio Healthcare
4. USV Pvt. Ltd enters the highly competitive German drug market by acquiring Juta Pharma GmbH
5. Biocon's Syngene inks pact with GSK for new drug discovery
6. India based Centaur Pharma and Kibow Biotech USA announced a strategic long-term alliance to market Renadyl in India.
7. Roivant snags Chinese rights to Nabriva’s antibiotic in $95M deal
8. AstraZeneca signs immuno-oncology deal with Compugen for $200M
9. Laborie pens $239M Cogentix buyout to boost urology unit
10. Biogen pays Pfizer $75M for experimental drug to treat schizophrenia
11. Aptose signs $125M-plus BET inhibitor deal with Ohm Oncology
12. Eisai and Nichi-Iko pharmaceutical enter into strategic alliance agreement
13. Beacon and Takeda initiate multi-year drug discovery collaboration
14. Eisai and Merck enter global strategic oncology collaboration for Lenvima®

Updates at Aagami:

1. Aagami registered for BIO International Convention 2018 to be held in Boston June 4-7. Meeting calendar open now. 
2. Aagami gets an assignment from a new client based in Illinois